Nitro-oleic acid is a novel anti-oxidative therapy for diabetic kidney disease

American Journal of Physiology - Renal Physiology

Volumn 305, Issue 11, 2013, Pages

  Menon, Madhav C ^a   Chuang, Peter Y ^a   He, John C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ALCOHOL; BARDOXOLONE; FATTY ACID; GLYCERYL TRINITRATE; LOSARTAN; NITROGEN OXIDE; OLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE C; RUBOXISTAURIN; SULODEXIDE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; DIABETES MELLITUS; DIABETIC KIDNEY DISEASE; DIABETIC PATIENT; EDITORIAL; ENZYME ACTIVATION; HUMAN; HYPERGLYCEMIA; KIDNEY DISEASE; KIDNEY FAILURE; NITRATION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; UNSPECIFIED SIDE EFFECT;

EID: 84888773407     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00489.2013     Document Type: Editorial

References (28)

1. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, Investigators RS. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
2. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
3. Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the US continues to decline. Diabetes Care 33: 73-77, 2010.
4. Centers for Disease Control and Prevention. Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes-United States and Puerto Rico, 1996-2007. MMWR Morb Mortal Wkly Rep 59: 1361-1366, 2010.
5. Chuang PY, Menon MC, He JC. Molecular targets for treatment of kidney fibrosis. J Mol Med 91: 549-559, 2013.
6. Cole MP, Rudolph TK, Khoo NK, Motanya UN, Golin-Bisello F, Wertz JW, Schopfer FJ, Rudolph V, Woodcock SR, Bolisetty S, Ali MS, Zhang J, Chen YE, Agarwal A, Freeman BA, Bauer PM. Nitrofatty acid inhibition of neointima formation after endoluminal vessel injury. Circ Res 105: 965-972, 2009.
7. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 107: 1058-1070, 2010.
8. Jain K, Siddam A, Marathi A, Roy U, Falck JR, Balazy M. The mechanism of oleic acid nitration by *NO(2). Free Radic Biol Med 45: 269-283, 2008.
9. Kansanen E, Jyrkkanen HK, Volger OL, Leinonen H, Kivela AM, Hakkinen SK, Woodcock SR, Schopfer FJ, Horrevoets AJ, Yla-Herttuala S, Freeman BA, Levonen AL. Nrf2-dependent and-independent responses to nitro-fatty acids in human endothelial cells: identification of heat shock response as the major pathway activated by nitro-oleic acid. J Biol Chem 284: 33233-33241, 2009.
10. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14: 439-447, 2000.
11. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993.
12. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study G. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
13. Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, Tsai TJ. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 16: 2702-2713, 2005.
14. Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis 52: 464-474, 2008.
15. Liu H, Jia Z, Soodvilai S, Guan G, Wang MH, Dong Z, Symons JD, Yang T. Nitro-oleic acid protects the mouse kidney from ischemia and reperfusion injury. Am J Physiol Renal Physiol 295: F942-F949, 2008.
16. Liu S, Jia Z, Zhou L, Liu Y, Ling H, Zhou SF, Zhang A, Du Y, Guan G, Yang T. Nitro-oleic acid protects against adriamycin-induced nephropathy in mice. Am J Physiol Renal Physiol (First published March 13, 2013). doi:10.1152/ajprenal.00656.2012.
17. Liu Y, Jia Z, Liu S, Downton M, Liu G, Du Y, Yang T. Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice. Am J Physiol Renal Physiol (First published August 14, 2013). doi:10/1152/ajprenal.00157.2013.
18. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macia M, Mendez ML, Garcia J. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33: 458-463, 1999.
19. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471, 2007.
20. Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC, Collaborative Study G. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 23: 123-130, 2012.
21. Rossing P. Diabetic nephropathy: could problems with bardoxolone methyl have been predicted? Nat Rev Nephrol 9: 128-130, 2013.
22. Schopfer FJ, Cole MP, Groeger AL, Chen CS, Khoo NK, Woodcock SR, Golin-Bisello F, Motanya UN, Li Y, Zhang J, Garcia-Barrio MT, Rudolph TK, Rudolph V, Bonacci G, Baker PR, Xu HE, Batthyany CI, Chen YE, Hallis TM, Freeman BA. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions. J Biol Chem 285: 12321-12333, 2010.
23. Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27: 130-143, 2007.
24. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28: 2686-2690, 2005.
25. Wang H, Liu H, Jia Z, Guan G, Yang T. Effects of endogenous ppar agonist nitro-oleic acid on metabolic syndrome in obese zucker rats. PPAR Res 2010: 601562.
26. Wang H, Liu H, Jia Z, Olsen C, Litwin S, Guan G, Yang T. Nitro-oleic acid protects against endotoxin-induced endotoxemia and multiorgan injury in mice. Am J Physiol Renal Physiol 298: F754-F762, 2010.
27. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67: 799-812, 2005.
28. Zhang J, Villacorta L, Chang L, Fan Z, Hamblin M, Zhu T, Chen CS, Cole MP, Schopfer FJ, Deng CX, Garcia-Barrio MT, Feng YH, Freeman BA, Chen YE. Nitro-oleic acid inhibits angiotensin II-induced hypertension. Circ Res 107: 540-548, 2010.